Clinical trial · Interventional
Efficacy and Safety of TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Breast Cancer
Study to Assessment the Efficacy and Safety of Joint TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Operable Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Select the postmenopausal patients with breast cancer who is confirmed by core needle biopsy and at the clinical stage T2-4N0-2M0.Treat them with 4 cycles of TAC as neoadjuvant chemotherapy (Docetaxel was 75mg/m2, the EPI 60mg/m2 and the CTX 600mg/m2,21day/cycle).At the same time give daily oral exemestane 25mg for 12 weeks.Then assess the efficacy and safety of TAC and Exemestane.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Exemestane | Drug | Exemestane | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Exemestane
- description
- Exemestane for neoadjuvant chemotherapy
- interventionNames
- Drug: Exemestane
Primary outcomes (1)
- measure
- therapeutic assessment
- timeFrame
- 6 months
- description
- therapeutic assessment
Secondary outcomes (1)
- measure
- Adverse reactions and disease-free survival
- timeFrame
- 2 years
- description
- Adverse reactions and disease-free survival
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: 1. Karnofsky ≥ 70 2. Provision of informed consent 3. Pathological confirmation of invasive ductal carcinoma and estrogen receptor is positive 4. Tumor stage(TNM):T2-4bN0-3M0 5. Premenopausal woman 6. Not previously received treatment with bisphosphonate 7. Laboratory criteria: * PLT ≥ 100\*109/L * WBC ≥ 4000/mm3 * HGB ≥ 10g/dl * GOT,GPT,ALP ≤ 2\*ULN * TBIL,DBIL,CCr ≤ 1.5\*ULN Exclusion Criteria: 1. Pregnant or lactation woman 2. History of organ transplantation 3. With mental disease 4. With severe infection or active gastrointestinal ulcers 5. With severe liver disease (such as cirrhosis), kidney disease, respiratory disease or diabetes 6. Disease-free period of other malignant tumor is less than 5 years(except cured basal cell skin cancer and cervical carcinoma in situ) 7. With heart disease 8. Experimental drug allergy
References
Publications (0)
Data not yet available